Chest
CLINICAL PRACTICE GUIDELINESMedical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines
Section snippets
Update of Treatment Guidelines
A consensus panel convened by the ACCP developed guidelines for the diagnosis and treatment of PAH that were published in 2004.9 Subsequently, several important clinical trials have been published and new treatments have received regulatory approval. In addition, add-on and combination therapy are being explored, which promise to open new therapeutic avenues.
Therefore, the Health and Science Policy Committee of the ACCP authorized an update of the medical treatment guidelines.1 Lewis Rubin, MD,
Calcium-Channel Antagonists
A small number of patients with IPAH, who demonstrate a favorable response to acute vasodilator testing at the time of cardiac catheterization, will do well with calcium-channel blocker (CCB) therapy. Since publication of the original ACCP guidelines, an important article10 has further clarified the role of CCBs in the IPAH population. Sitbon and colleagues10 reported results of a retrospective analysis of 557 IPAH patients tested acutely with IV epoprostenol or inhaled nitric oxide. Using a
Epoprostenol
In a 12-week, prospective, multicenter, randomized, controlled, open-label trial,11 continuously IV infused epoprostenol plus conventional therapy (including oral vasodilators [CCBs], anticoagulation, diuretic, digoxin, and oxygen) was compared to conventional therapy alone in 81 patients with severe IPAH (NYHA class III or IV). Exercise capacity improved in the 41 patients treated with epoprostenol (median 6 min walk [6MW] distance, 362 m at 12 weeks, vs 315 m at baseline), and decreased in
Bosentan
The first randomized, double-blind, placebo-controlled, multicenter study22 of bosentan demonstrated an improvement in the 6MW distance of 70 m (from 360 ± 19 m at baseline to 430 ± 14 m at week 12; p < 0.05), whereas no improvement was seen with placebo (355 ± 25 m at baseline and 349 ± 44 m at week 12). Treatment with bosentan also improved cardiopulmonary hemodynamics and functional class. Asymptomatic increases in hepatic aminotransferases were observed in two bosentan-treated patients. In
Sildenafil
Sildenafil is a potent and highly specific phosphodiesterase 5 inhibitor that has been previously approved for erectile dysfunction. Several reports313233 of nonrandomized, single-center studies of PAH patients treated with long-term sildenafil suggested promise for sildenafil as a therapeutic agent. A double-blind, placebo-controlled study (the Sildenafil Use in Pulmonary Arterial Hypertension-1 study,34) randomly assigned 278 patients with symptomatic PAH (either idiopathic or associated with
Summary
The paradigm for treatment of PAH continues to advance rapidly. Multicenter randomized clinical trials (RCTs) have provided a basis for evidence-based practice. The treatment algorithm provided (Fig 1) attempts to summarize the current approach to therapy for PAH. The following brief overview, organized by functional class, is intended to facilitate clinical application of the algorithm. It should be noted that functional class is difficult to quantify, and may vary among patients and care
References (34)
- et al.
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004)Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004)- et al.
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival
J Am Coll Cardiol
(2002) - et al.
Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial
Chest
(2006) - et al.
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
Lancet
(2001)
Effects of long-term bosentan in children with pulmonary arterial hypertension
J Am Coll Cardiol
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
J Am Coll Cardiol
Ambrisentan therapy for pulmonary arterial hypertension
J Am Coll Cardiol
Methodology and grading for pulmonary hypertension evidence review and guideline development
Chest
Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
Circulation
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group
N Engl J Med
Cited by (456)
Solubility determination and thermodynamic properties calculation of macitentan in mixtures of ethyl acetate and alcohols
2021, Journal of Chemical ThermodynamicsCitation Excerpt :It causes a substantial clinical and economic burden, and PAH related hospital admissions decreased between 2001 and 2012, the mean charge and length of stay per PAH related admission have increased with no significant decline in inpatient mortality. However, significant improvements have been made in treatment recently [5–7]. Macitentan (CAS NO. 441798-33-0, Fig. 1) is a novel dual endothelin receptor antagonist, and inhibits contractile and proliferative responses to vascular smooth muscle and delays progression of PAH disease, including death, intravenous or subcutaneous injection of prostacyclin drug-like or PAH symptoms worsen [8–13].
Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension
2018, International Journal of CardiologyImpact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis
2018, Journal of Heart and Lung Transplantation
Dr. Badesch has received grant monies from the National Institutes of Health. He has received grant monies from GlaxoSmithKline, United Therapeutics/LungRx, Actelion, Lilly/ICOS, Encysive, Pfizer, Myogen/Gilead, and CoTherix. He has received consultant fees from GlaxoSmithKline, Actelion, Myogen/Gilead, CoTherix, Pfizer, United Therapeutics, Mondo-Biotech, Biogen IDEC, PR Pharmaceuticals, Forrests Labs, Scios, Amgen, Biovale Pharmaceuticals/Clarus Health, and Johnson & Johnson. He has served on the speaker's bureau for GlaxoSmithKline, Actelion, Myogen/Gilead, Encysive, CoTherix, Pfizer, United Therapeutics, Mondo-Biotech, and Biogen IDEC. He has served on the board of directors for the Pulmonary Hypertension Association and the American Thoracic Society.
Dr. Abman has served as a scientific advisor for INO Therapeutics.
Dr. Simonneau has received grant monies from, served on the speaker's bureau for, and served on the advisory committees for Actelion, Pfizer, Schering, United Therapeutics, and GlaxoSmithKline.
Dr. Rubin has received university grant monies from the National Heart, Lung, and Blood Institute. He has received grant monies from Actelion, Pfizer, United Therapeutics, Mondo-Biotech, MD Primer, and Gilead. He is a shareholder in LungRx. He has received consultant fees from the National Heart, Lung, and Blood Institute; Actelion; Pfizer; United Therapeutics; ProQuest; Bayer Schering; and Mondo-Biotech. He is on the advisory committees for Actelion, Pfizer, LungRx, MD Primer, and Encysive.
Dr. McLaughlin has received grant monies from Actelion, Encysive, LungRx, Pfizer, and United Technologies. She has served on the speaker's bureau and advisory committees for Actelion, Gildead, and Pfizer.